Autoimmune Disease Series: Will Biologics Emerge as New Treatments for Reactive Arthritis?Decision ResourcesDecember 5, 2008 26 Pages - SKU: DECR2027047 |
|
541711 Research and Development In Biotechnology: State Industry Market Evaluator
6/1/2012 | published by: BizMiner
This State Industry Market Evaluator reports on industry trends broken out for each US state. Each state sub-report is comprised of eight pages of data. Statistics are displayed for 2008-2009-2010 and 2011q2 for these measures:
|
more...
|
$699.00
|
|
Autoimmune Disorders Therapeutics Market to 2017 - Launch of Gilenya and Benlysta to Drive the Growth of Multiple Sclerosis and Systemic Lupus Erythematosus Therapeutic Segments
4/30/2012 | published by: GBI Research
Autoimmune Disorders Therapeutics Market to 2017 - Launch of Gilenya and Benlysta to Drive the Growth of Multiple Sclerosis and Systemic Lupus Erythematosus Therapeutic Segments Summary GBI Research, the leading business intelligence provider, has released its latest
|
more...
|
$3,500.00
|
|
Global Biotechnology
4/4/2012 | published by: IBISWorld
Global Biotechnology Biotechnology is the application of science and technology to living organisms as well as parts, products and models thereof, to alter living or non-living materials for the production of knowledge and biotechnology products and
|
more...
|
$935.00
|
|
Biotechnology in the US - Industry Market Research Report
3/26/2012 | published by: IBISWorld
Biotechnology in the US Wave of the future : Demand for cutting-edge medicines and treatments will result in strong growth for the Biotechnology industry. While it was not entirely immune to the recession, healthcare reform, environmental concerns
|
more...
|
$910.00
|
|
Systemic Lupus Erythematosus – Pipeline Review, H1 2012
2/27/2012 | published by: Global Markets Direct
Systemic Lupus Erythematosus – Pipeline Review, H1 2012 Summary Global Markets Direct’s, 'Systemic Lupus Erythematosus - Pipeline Review, H1 2012', provides an overview of the Systemic Lupus Erythematosus therapeutic pipeline. This report provides information on the therapeutic
|
more...
|
$500.00
|
|
Rheumatoid Arthritis – Pipeline Review, H1 2012
2/27/2012 | published by: Global Markets Direct
Rheumatoid Arthritis – Pipeline Review, H1 2012 Summary Global Markets Direct’s, 'Rheumatoid Arthritis - Pipeline Review, H1 2012', provides an overview of the Rheumatoid Arthritis therapeutic pipeline. This report provides information on the therapeutic development for Rheumatoid
|
more...
|
$500.00
|
|
Gouty Arthritis (Gout) – Pipeline Review, H1 2012
2/27/2012 | published by: Global Markets Direct
Gouty Arthritis (Gout) – Pipeline Review, H1 2012 Summary Global Markets Direct’s, 'Gouty Arthritis (Gout) - Pipeline Review, H1 2012', provides an overview of the Gouty Arthritis (Gout) therapeutic pipeline. This report provides information on the therapeutic
|
more...
|
$500.00
|
|
Antibody Partnering Terms and Agreements
3/1/2012 | published by: Current Partnering
The Antibody Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the antibody partnering deals and agreements entered into by the worlds leading healthcare companies.
The report provides a
|
more...
|
$2,695.00
|
|
Psoriasis – Pipeline Review, H1 2012
2/27/2012 | published by: Global Markets Direct
Psoriasis – Pipeline Review, H1 2012 Summary Global Markets Direct’s, 'Psoriasis - Pipeline Review, H1 2012', provides an overview of the Psoriasis therapeutic pipeline. This report provides information on the therapeutic development for Psoriasis, complete with latest
|
more...
|
$500.00
|
|
Osteoarthritis Pain – Pipeline Review, H1 2012
2/27/2012 | published by: Global Markets Direct
Osteoarthritis Pain – Pipeline Review, H1 2012 Summary Global Markets Direct’s, 'Osteoarthritis Pain - Pipeline Review, H1 2012', provides an overview of the Osteoarthritis Pain therapeutic pipeline. This report provides information on the therapeutic development for Osteoarthritis
|
more...
|
$500.00
|
Related Markets
Autoimmune Reports
- Autoimmune Disorders Therapeutics Market to 2017 - Launch of Gilenya and Benlysta to Drive the Growth of Multiple Sclerosis and Systemic Lupus Erythematosus Therapeutic Segments
- Endpoints - Clinical Trials in Autoimmune Disorders - Multiple Primary and Secondary Endpoints are Increasingly Being Applied to Ensure Success
- Liver Disease Treatments: The Global Market
- Celiac Disease - Pipeline Assessment and Market Forecasts to 2019
- Orphan Autoimmune Disorders to 2017 - Strong Performance by Nplate and Promacta and Future Launches of Immunoglobulin Therapies will Drive the ITP Market
